Other
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2021
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Higher payments indicate active investment in external innovation and pipeline expansion.
Detailed definition
This metric tracks the net financial obligations or payments made to collaboration partners, specifically related to the...
Peer comparison
Common in biotechnology and pharmaceutical industries where R&D is often supplemented by external licensing.
Metric ID:
other_noncash_financing_or_investing_activities_collabor_f4a824Historical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $180.00M | $0.00 | $0.00 |
| YoY Change | — | — | — | -100.0% | — |
Range$0.00 – $180.00M
Avg YoY Growth-100.0%
Median YoY Growth-100.0%
Net payments due to CRISPR Therapeutics AG related to finite-lived intangible assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's net payments due to crispr therapeutics ag related to finite-lived intangible assets?
- Vertex Pharmaceuticals (VRTX) reported net payments due to crispr therapeutics ag related to finite-lived intangible assets of $0.00 in Q4 2025.
- What does net payments due to crispr therapeutics ag related to finite-lived intangible assets mean?
- Cash payments made to strategic partners for the acquisition of intangible assets.